References to Primary Literature
- ROCK DL: The molecular basis of latent infections by alphaherpesviruses. Semin. Virol. (1993) 4:157–165.
- FAWL RL, ROIZMAN 13: The molecular basis of herpes simplex virus pathogenicity. Semin. Virol. (1994) 5:261–271.
- AHMED R, MORRISON LA, KNIPE DM: Persistence of viruses. In: Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippincott-Raven Press, New York (1996):219–250.
- ROIZMAN B, SEARS AE: Herpes simplex viruses and their replication. In: The Human Herpes Viruses. Roizman B, Lopez C, Whitley RJ (Eds.), Raven Press, New York (1993):11–16.
- WARD PL, ROIZMAN B: Herpes simplex genes: blueprint for a successful human pathogen. Trends Genetics (1994) 10:267–274.
- CHA TA, TOM E, KEMBLE GW et al.: Human cytomega-lovirus clinical isolates carry at least 19 genes not found In laboratory strains. J. Virol. (1996) 70:78–83.
- MESRI EA, CESARMEN E, ARVANITAKIS L et al.: Human herpes virus-8 Kaposi's sarcoma-associated herpes-virus is a new transmissible virus that infects B cells. Exp. Med. (1996) 183:2385–2390.
- WHITE DO, FENNER FJ: Herpesviridae. In: Medical Virol-ogy. White DO, Fenner FJ (Eds.), Academic Press (1994):318–347.
- SACKS L, ALRABIAH F: Novel herpes treatments: a re-view. Exp. Opin. Invest. Drugs (1996) 5:169–183.
- BEUTNER KR: Valacklovir: a review of its antiviral activ-ity, pharmacokinetic properties, and clinical efficacy. Antiviral Res. (1995) 28:281–290.
- CIRELLI R, HERNE K, MCCRARY M, LEE P, TYRING SK: Fanwiclovir: a review of clinical efficacy and safety. Antiviral Res. (1996) 29:141–151.
- ARVIN AM: Varicella-zoster virus. In: Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippincott-Raven Press, New York (1996):2547–2586.
- ARVIN AM, MOFFAT JF, REDMAN R: Varicella-zoster virus: aspects of pathogenesis and the host response to natu-ral infection and varicella vaccine. Adv. Viral Res. (1996) 46:265–307
- COHEN JI, STRAUS SE: Varicella-zoster virus and its replication- In: Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippincott-Raven Press, New York. (1996):2525–2546.
- NIKKELS AF, PIERARD GE: Current therapies for shin-gles. Exp. Opin. Invest. Drugs (1996) 5:185–196.
- BRITT WJ, ALFORD CA: Cytomegalovirus. In: Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippincott-Raven Press, New York (1996):2493–2524.
- MELNICK JL, ADAM E, DEBAKEY ME: Cytomegalovirus and atherosclerosis. BioEssays (1995) 17:899–903.
- PLACHTER B, SINZGER C, JAHN G: Cell types involved in replication and distribution of human cytomega-lovirus. Adv. Viral. Res. (1996) 46:197–241.
- FISH KN, BRITT W, NELSON JA: A novel mechanism for persistence of human cytomegalovirus in macro-phages.]. Virol. (1996) 70: 1855-1862.
- RONDO K, KANESHIMA H, MOCARSKI ES: Human cy-tomegalovirus latent infection of granulocyte-macro-phage progenitors. Proc. Natl. Acad. Sci. USA (1994) 91:11879–11883.
- STENBERG RM, KERRY JA: Cytomegalovirus genes: their structure and function. Scand. J. Infect. Dis . (1995) S99:3–6.
- MOCARSKI ES: Cytomegaloviruses and their replication. In: Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippincott-Raven Press, New York (1996):2447–2492.
- GRIFFITHS PD: Parameters for the successful manage-ment of cytomegalovirus. Antiviral Chem. Chemother. (1995) 6\(Suppl. 1):7–11.
- YOUNG LS: Epstein-Barr virus: general features. In: Encyclopedia of Virology. Webster RG, Granoff A (Eds.), Academic Press (1995):404–409.
- RICKINSON AB, KIEFF E: Epstein-Barr virus. In: Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippincott-Raven Press, New York (1996):2397–2446
- THOMAS JA, ALLDAY MJ, CRAWFORD DH: Epstein-Barr virus-associated lymphoproliferative disorders in fin-munocompromised individuals. Adv. Cancer Res. (1991) 57:329–380.
- KLEIN G: Viral latency and transformation: the strategy of Epstein-Barr virus. Cell (1989) 58:5–8.
- KIEFF E: Epstein-Barr virus and its replication. In: Virol-ogy. Fields BN, Knipe DM, Howley PM (Eds.), Lippincott-Ra-ven Press, New York (1996):2343–2396.
- YAMANISHI K: Human herpesvirus 6. Int. Antiviral News (1996) 4:59–60.
- LUSSO P: Human herpesvirus 6 (HHV-6). Antiviral Res. (1996) 31:1–21.
- KRUEGER GRF, KLUEPPELBERG U, HOFFMAN A, ABLASHI DV: Clinical correlates of infection with human herpes-virus-6. In Vivo (1994) 8:457–486.
- CHALLONER PB, SMITH KT, PARKER JD et al.: Plaque-as-sociated expression of human herpesvirus 6 in multiple sclerosis. Proc. Natl. Acad. Sci. USA (1995) 92:7440–7444.
- HERNDON RM: Herpesviruses in multiple sclerosis. Arch. Neurol. (1996) 53:123–124.
- LUSSO P, GALLO RC: Human herpesvirus 6 in AIDS Immunol. Today (1995) 16:67–71.
- FRENICEL N, ROFFMAN E: Human herpesvirus 7. In: Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippin-cott-Raven Press, New York (1996):2609–2622.
- AMBROZIAK JA, BLACKBOURN DJ, HERNDIER BG et aL: Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science (1995) 268:582–583.
- Herpes viruses. In: Antiviral Chemotherapy. Jeffries DJ, DeClercq E (Eds.), J Wiley 8r Sons (1995):81–284.
- DUTIA BM: Ribonucleotide reductase induced by herpes simplex virus has a virus specified constituent.]. Gen. Virol. (1993) 64:513–521
- BRANDT C.R, SPENCER B, IMESCH P, GARNEAU M, DEZLEL R: Evaluation of a peptidomimetic ribonucleotide re-ductase inhibitor with a murine model of herpes sim-plex virus type 1 ocular disease, Antimicrobial Agents Chernother. (1996) 40:1078-1084. and analysis of the human cytomegalovirus UL80-en-
- BAUM EZ, BEBERNITZ GA, HULMES JD et a/ Expression and analysis of the human cytomegalovirus WO-encoded protease: identification of autoproteolytic sites.
- FRUH K, AHN K, DJABALLAH H el a1 Aviral inhibitor of peptide transporters for antigen presentation Nature 1 Mwl (1993) 67 497–506 (1995) 375 415–418
- FRIEDLAND JS Chemoklnes in vlial disease. Res Vzml (1996) 147 131–138
- MEINI E, FICKENSCHER �1, FLECKENSTEIN B Chemokine receptors and chemoklne-inducing molecuies of lymphotrophic herpesviruses. Immunol Today (1996) 17 199
- WIERTZ EJHJ, JONES TR, LEI SUN el a1 The human cytomegalovjrus US11 gene produd dislocates MHC c h s 1 heavy chains from the endoplasmic reticulum to the cytosol. Cell (1996) 84 769–779
- FARREL HE, MCLEAN CS, EFSTATHIOU S, INGLIS S, MIN SON AC Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deletea/
- LIU F, ROIZMAN B The promoter, transcription unlt and coding sequences of herpes simplex virus 1 family 35 proteins are contained withb and in frame with the u1.26 open reading Erame. J Mml (1991) 65 206–212
References to Patent Literature
- KOBAYASHI KAKO KK, JP7247216 (1995).
- ZYMA SA, GB2288734 (1995).
- ZYMA SA, EP-679390 (1995).
- DR RENTSCHLER ARZNEIMITTEL GMBH & CO., W09531201 (1995).
- WELLCOME FDN. LTD., W09505179 (1995).
- SMITHKLINE BEECHAM PLC., GB2282759 (1995).
- HOECHST AG, EP-661058 (1995).
- SMITHKLINE BEECHAM PLC., W09513073 (1995).
- SMITHKLINE BEECHAM PLC., W09513074 (1995).
- SMITHKLINE BEECHAM PLC., W09509632 (1995).
- SMlTHKLINE BEECHAM PLC., W09517190 (1995).
- F HOFFMANN-LA ROCHE AG, EP-694547 (1995).
- BRISTOL-MYERS SQUIBB CO., EP-63W97 (1995).
- BRISTOL-MYERS SQUIBB CO., US5414000 (1995).
- BRISTOL-MYERS SQUIBB CO., US5414096 (1995).
- BURROUGHS WELLCOME CO., US5399580 (1995).
- WELLCOME FDN. LTD., W09601833 (1995).
- AJINOMOTO CO., INC., EP-649840 (1995).
- AJINOMOTO CO., INC., EP454473 (1995).
- BORWNG PHARM CO. LTD., EP-657465 (1995).
- NIPPON KAYAKU KK, JP7126282 (1995).
- ELI LILLY & CO., US5430026 (1995).
- CIBA-GEIGY AG, EP-629633 (1995).
- DAIICHI SEIYAKU KK, JP7048374 (195).
- MITSUBISHI KASEI COW., EP-632048 (1995).
- GENSET, W09504141 (1995).
- ROMAN KOGYO KK, JP7206892 (1995).
- ISISPIIARM, INC., W09528341 (1995).
- ISISPHARM, INC., US5442049 (1995).
- HYBRIDON, INC., W09532213 (1995).
- HYBRIDON, INC., W09522554 (1995).
- ISISPHARM, INC., W09526204 (1995).
- BIO-MEGA, US5484771 (1995).
- GIBSON DW, US543074 (1995).
- GD SEARLE, W09529897 (1995).
- SEIGAKU CORP., W09427607 (195).
- UNIVERSITY OF MICHIGAN, W09523151 (1995).
- SRI INTERNATIONAL, W09504059 (1995).
- SCHERING CORP., US5459146 (1995).
- SHOWA SHELL SEKIYU KK, JP7070166 (1995).
- SOYAKU GIJUTSU KENKYUJO KK, JP7277963 (1995).
- SANWA KAGAKU KENKYUJO KK, JP635748 (1995).
- WELLCOME FDN. LTD., W09507910 (1995).
- NIPPON SHOJI KK, JP179467 (1995).
- ALLELIX BIOPHARM, INC., W09511038 (1995).
- BAYER AG, EP-611776 (1995).
- ALLELIX BIOPHARM, INC., W09514027 (1995).
- COMMONWEALTH SCI. & IND. RES. ORG., W09531202 (1995).
- SCOTGEN PHARM., INC., W09531546 (1995).
- AND02 PHARM. CORP., W09504080 (1995).
- SCRIPPS RES. INST., W09518634 (1995).
- MERCK & CO., INC., W09517503 (1995).
- BRITISH BIOTECH PHARM. LTD., W09601900 (196).
- AVIRON, W09529991 (1995).
- SMITHKLINE BEECHAM CORP., W09506055 (1995).
- AUSTRALIAN NATIONAL UNIVERSm, W09514487 (1995).
- SMWHKUNE BEECIIAM BIOLOGICALS SA, W09516779 (1995).
- QUEENSIAND INST. OF MED. RES., W09524925 (1995).
- AMRON, W09528488 (1995).
- SMITHKLINE BEECHAM BIOLOGICALS SA, W09531555 (1995).
- CANTAB PHARM. RES. LTD., W0950339 (1995).
- HARVARD COLLEGE, W09518852 (1995).
- MRC, W09520049 (1995).
- PHARMA MAR SA, EP-647645 (1995).